Using Cardiac MRI to Study Blood Flow in Different Types of Hypertrophic Cardiomyopathy Including Genetic Carriers and Family Members

What this Trial Is About

Researchers are evaluating myocardial perfusion abnormalities using cardiac magnetic resonance CMR perfusion imaging in patients with hypertrophic cardiomyopathy HCM types, including sarcomeric and non-sarcomeric HCM, Anderson-Fabry disease, and cardiac amyloidosis. The study also includes first-degree relatives of affected patients and genetic mutation carriers. By comparing blood flow and perfusion patterns, the study aims to identify distinctive signs that may improve diagnosis, risk assessment, and understanding of ischemias role in disease progression and outcomes. This observational study involves imaging participants hearts with CMR to assess myocardial perfusion. Participants include those diagnosed with hypertrophic cardiomyopathy or related genetic conditions, their close relatives, and genetic mutation carriers. The study will analyze quantitative and qualitative perfusion defects at the start and again after 36 months to observe changes over time. Participants will undergo cardiac magnetic resonance imaging at baseline and after 36 months. Researchers will measure and compare perfusion defects using both quantitative and qualitative methods. The study focuses on gathering detailed imaging data to understand myocardial blood flow differences among the various cardiomyopathy types and genetic profiles. The total participation time involves these two main imaging timepoints, with ongoing observation to support long-term insights.

Myocardial Perfusion CMR for Differentiating and Characterizing Hypertrophic Cardiomyopathy Phenotypes